文献速递妇科

DKK1是DKN-01治疗反应的预测性生物标志物:复发子宫内膜癌女性2期篮式研究结果

DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
PubMed 文献 · Gynecol Oncol · 2023-03-29

这项开放标签2期篮式研究采用两阶段设计,纳入子宫内膜癌患者,DKN-01单药或联合每周紫杉醇由研究者决定。DKK1高表达者单药客观缓解率25.0% vs 低表达者0%,疾病控制率62.5% vs 6.7%,中位无进展生存期4.3 vs 1.8个月。

要点

  • DKK1高表达者DKN-01单药疾病控制率62.5%,低表达者6.7%。
  • DKK1高表达者联合紫杉醇疾病控制率55%,低表达者44%。
  • DKN-01单药及联合紫杉醇耐受性良好。

核心结论

  • DKN-01在肿瘤DKK1高表达的子宫内膜癌患者中显示出有前景的临床活性,且耐受性良好,DKK1高表达常对应Wnt激活突变。
  • 未来开发将聚焦于DKK1高表达子宫内膜癌患者中DKN-01联合免疫治疗。

研究设计与样本

  • 开放标签、2期篮式研究,采用两阶段设计,纳入子宫内膜癌和铂类耐药/难治性上皮性卵巢癌患者。
  • DKN-01以单药或联合每周紫杉醇给药,由研究者决定。
  • 所有患者入组前接受NGS检测,肿瘤组织治疗前及第1周期后(如有)通过RNAscope检测DKK1表达。
  • 要求至少50%的患者具有直接或间接的Wnt信号通路改变。
  • 本文报告子宫内膜癌总体人群及按DKK1表达分组的结果。

主要发现

  • DKN-01单药在DKK1高表达vs低表达患者中:客观缓解率25.0% vs 0%,疾病控制率62.5% vs 6.7%,中位无进展生存期4.3 vs 1.8个月,总生存期11.0 vs 8.2个月。
  • DKN-01联合紫杉醇在DKK1高表达vs低表达患者中:疾病控制率55% vs 44%,中位无进展生存期5.4 vs 1.8个月,总生存期19.1 vs 10.1个月。
  • Wnt激活突变与更高的DKK1表达相关。
  • DKN-01单药及联合紫杉醇耐受性良好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Dickkopf-1 (DKK1) is a Wnt signaling modulator promoting tumor growth, metastasis, angiogenesis, and immunosuppression by regulating innate immunity. DKK1 is over-expressed in gynecologic cancers and is associated with shortened survival. DKN-01 is a humanized monoclonal antibody with DKK1 neutralizing activity that may provide clinical benefit to patients whose tumors have overexpression of DKK1 or Wnt genetic alterations. METHODS: We conducted an open-label, Phase 2 basket study with 2-stage design in patients with endometrial carcinoma (EC) and platinum-resistant/refractory epithelial ovarian cancer. DKN-01 was administered either as monotherapy or in combination with weekly paclitaxel at investigator's discretion. All patients underwent NGS testing prior to enrollment; tumor tissue was also tested for DKK1 expression by RNAscope pre-treatment and after cycle 1 if available. At least 50% of patients were required to have a Wnt signaling alteration either directly or tangentially. This publication reports results from the EC population overall and by DKK1-expression. RESULTS: DKN-01 monotherapy and in combination with paclitaxel was more effective in patients with high DKK1-expressing tumors compared to low-expressing tumors. DKN-01 monotherapy demonstrated an objective response rate [ORR] of 25.0% vs. 0%; disease control rate [DCR] of 62.5% vs. 6.7%; median progression-free survival [PFS] was 4.3 vs. 1.8 months, and overall survival [OS] was 11.0 vs. 8.2 months in DKK1-high vs DKK1-low patients. Similarly, DKN-01 in combination with paclitaxel demonstrated greater clinical activity in patients with DKK1-high tumors compared to DKK1-low tumors: DCR was 55% vs. 44%; median PFS was 5.4 vs. 1.8 months; and OS was 19.1 vs. 10.1 months. Wnt activating mutations correlated with higher DKK1 expression. DKN-01 was well tolerated as a monotherapy and in combination with paclitaxel. CONCLUSIONS: Collectively, data demonstrates promising clinical activity of a well-tolerated drug, DKN-01, in EC patients with high tumoral DKK1 expression which frequently corresponded to the presence of a Wnt activating mutation. Future development will focus on using DKN-01 in DKK1-high EC patients in combination with immunotherapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Arend R, Dholakia J, Castro C, et al. DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma. Gynecol Oncol. 2023. PMID: 37001446. doi:10.1016/j.ygyno.2023.03.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。